**Prepared on March 9, 2018**

**Kenneth Paul Olive, Ph.D.**

1130 St. Nicholas Ave

ICRC Bldg, Room 217a

New York, NY 10032

212-851-4678

kenolive@columbia.edu

Birthplace Ridgewood, NJ

CitizenshipUSA

**Academic Appointments:**

8/2017 – present Director, Precision Therapeutics and Imaging Shared Resource, Herbert Irving Comprehensive Cancer Center (HICCC)

3/2012 – 8/2017 Director, Small Animal Imaging Shared Resource, HICCC

1/2010 – present Assistant Professor, Departments of Medicine, Division of Digestive and Liver Diseases

1/2010 – present Assistant Professor, Department of Pathology and Cell Biology

1/2010 – present Member, Columbia University Herbert Irving Comprehensive Cancer Center

**Education**

9/1998 – 1/2005 **Ph.D. Biology**, **Massachusetts Institute of Technology**

Sponsor: Prof. Tyler Jacks

Thesis: “The Germline– and Tissue–Specific Effects of Endogenous Point-Mutant p53”

Citations: Olive et. al, **Cell**, Vol. 119, 847–860, 2004

Jackson & Olive et. al, **Cancer Research**, 65(22): 10280-10288, 2005

9/1994 – 5/1998 **B.S. Biology**, **Bucknell University**

Department of Biology, Magna Cum Laude, with Honors

Thesis: “Increased c-myb protooncogene expression in mouse bone cells transfected with a fragment of the chicken c-myb gene: induction of a tumorigenic phenotype”

**Training**

9/2006 –12/2009 **Postdoctoral Fellowship**, **Cambridge Research Institute/University of Cambridge**

Advisor: David Tuveson, pancreatic cancer translational therapeutics

1/2005 – 8/2006 **Postdoctoral Fellowship, University of Pennsylvania**

Advisor: David Tuveson, pancreatic cancer translational therapeutics

**Honors and Awards**

2015 Ruth Siegel Prize for Excellence in Pancreatic Cancer Research (Columbia University)

2014 Subject of Feature article: “The Littlest Patient”, **Science**, J. Couzin-Frankel, 346: 24-27

2009 AACR Scholar-in-Training Award, MMHCC Meeting, San Francisco.

2006 – 2009 NIH Ruth L. Kirschstein National Research Service Awards, Postdoctoral Fellowship

2006 AACR Scholar-in-Training Award, Gerald B. Grindey Memorial Fund

2003 – 2004 Koch Graduate Fellowship in Cancer Research

1998 John T. Lowry Jr. Prize, most outstanding graduate, Dept. of Biology, Bucknell University

**Academic Service**

2017 – present Established and direct the HICCC Precision Therapeutics and Imaging Shared Resource

2016 – 2017 Reviewer, Irving Institute Pilot Award and Educational Programs

2015 Established the small animal MRI service for HICCC

2012 – 2014 Institutional Animal Care and Use Committee (IACUC)

2011 – 2012 Pancreas SPORE Organizing Committee

2011 Established Small Animal Imaging Shared Resource within HICCC

2010 – present The Pancreas Center, Executive Committee

2010 – present Interviewing for graduate programs (Pathobiology, Integrated CMBS, Pharmacology, and MD/PhD), performing 10 – 20 interviews per year

*Conference Organization*

2017 Principal organizer, “2017 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY

2015 Principal organizer, “2015 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY

2014 Principal Organizer, New York Academy of Sciences Symposium, "Pancreatic cancer: targeting key vulnerabilities", New York, NY

2013 Principal organizer, “2013 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY

2012 Organizer, New York Academy of Sciences Symposium: “Phosphatidylserine asymmetry and Cell Survival: Therapeutic Applications in Cancer and Infectious Disease”, New York, NY

2012 Organizer, New York Academy of Sciences Symposium: “Targeting hypoxia for cancer imaging and therapy”, New York, NY

2012 Principal organizer, “Pancreatic cancer: translating new ideas”, New York, NY

2011 Principal organizer, “2011 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY

**Professional Organizations, Societies, and Service**

*Memberships and Positions*

2010 – present Member, American Association for Cancer Research

2010 – 2015 Member, New York Academy of Sciences Cancer Signaling Discussion Group

2010 – 2013 Member, American Gastroenterological Association

2005 – 2009 Associate Member, American Association for Cancer Research

*Consultative*

2017 NIH Study Section, Ad Hoc: ZRG1 BMCT-C

2016 – present Scientific Advisory Board, Elstar Therapeutics

2015 NIH Study Section, Ad Hoc: Cancer Genetics

2013 NIH Study Section, F09 Fellowship: Oncological Sciences

2012 – 2015 Scientific Advisory Board, Lustgarten Foundation for Cancer Research

2012 NIH Study Section, ZRG1 BMCT-C(09)

*Journal Reviewer*

2018 Nature

2017 Nature, Cancer Cell (2), Carcinogenesis

2016 Science, Cancer Cell, Clinical Cancer Research

2015 Nature Communications, Cell, Nature Medicine

2014 Nature (2), Nature Medicine, Cancer Cell, Clinical Cancer Research

2013 Nature (2)

2012 Oncogene, PNAS

2011 Clinical Cancer Research, Oncogene, European Journal of Cancer

2010 Science Translational Medicine, Clinical Cancer Research, J. Hepatology, J. Cell Science

**Fellowship and Grant Support**

*Present support*

**Translational Clinical Program Olive (PI)** 2/1/2018 – 1/31/2021 2.4 months

**Lustgarten Foundation for Pancreatic Cancer Research** $2,230,654 total costs

“Clinical translation of regulatory network-based precision medicine for pancreatic cancer”

This program-level grant will support a clinical trial of network-based precision medicine for pancreatic cancer as well as a complementary preclinical research effort to develop combination therapies.

**IION Award Olive (PI)** 9/1/2017 – 8/31/2019 2.4 months

**Bristol Meyes Squibb** $422,685 total direct costs

“Parsing local immunosuppression in pancreatic ductal adenocarcinoma”

A computational analysis of pancreatic tumors combined with immunophenotyping of cellular popluations across a large cohort of human PDA cases.

**1R01 NCI 1R01CA215607-01 Olive (PI)** 3/1/2017 – 2/28/22 2.4 months

**NIH/NCI** $252,858 direct per year

“Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer”

Metabolism experiments designed to explore the function of cysteine in pancreatic cancer and its relationship to ferroptosis (an ROS-mediated cell death), using cell culture, metabolomics, and mouse models.

**CCSG Administrative Supp. Olive (PI)** 10/1/2016 – 9/31/20182.4 months

**NIH/NCI** $315,000 total direct

“Combination targeting of fibroblast and myeloid populations to improve immune responses in pancreatic cancer”. This study will use both systems and experimental biology approaches to study the interactions of cancer associated fibroblasts and myeloid cells in the pancreatic cancer stroma. These populations will be targeted therapeutically to increase CD8 T-cell responses in pancreatic cancer.

**1U54CA209997-01 Califano (Co-Inv)** 8/8/16 – 7/31/21 0.6 months

**NIH/NCI** $41,121 of $1,244,907 annual direct

“Centers for Cancer Systems Therapeutics (CaST)”

This subaward will fund systems biology investigations into the cellular heterogeneity of pancreatic cancer.

**NCI 3 P30 CA13696-40 Emerson (Core Director)** 07/01/14 - 06/30/19 0.92 months

**NIH/NCI** Role: Director, Small Animal Imaging SR $183,795 total direct (core)

This Cancer Center Support Grant provides support for the Herbert Irving Comprehensive Cancer Center, and specifically to the Small Animal Imaging Shared Resource.

*Past Support*

**Sponsored Research Project Olive (PI)** 12/1/14 – 10/31/17 0.6 months

**Merck Oncology** $357,143 total direct

“Preclinical evaluation of PD-1 inhibitor combinations in pancreatic cancer”

This study will evaluate combinations of PD-1, AMD3100, and gemcitabine in a genetically engineered mouse model of pancreatic cancer.

**Imaging RFA Olive (PI)** 8/1/2013 – 7/31/2017 1.2 months

**Lustgarten Foundation** (No cost extension)$1,066,962 total direct costs

“Focused Ultrasound Technologies for Diagnosis, Monitoring, and Treatment of Pancreatic Cancer”

Preclinical development and clinical translation of a novel functional ultrasound technology for pancreatic cancer. Collaboration with Dr. Elisa Konofagou, Dept. of Biomedical Engineering.

**Philanthropic donation** 12/31/14 - 12/30/16

**Sue Mirza**

A $225,000 gift to the Pancreas Center for the purpose of funding a genomic medicine project in the Olive laboratory.

**Precision Medicine Pilot Grant Olive (PI)** 2/1/16 – 1/31/2017 0.36 months

**Irving Institute for Clinical and Translational Research**  $100,000 total direct

“Precision targeting of pancreatic cancer regulatory networks”

This study will perform perturbation analysis of pancreatic tumor cells to identify agents and combinations that inhibit the activity of pancreatic cancer master regulator proteins that were identified in a large-scale systems biology project in our lab.

**1R01CA157980-01 Olive (PI)** 3/1/2011 – 12/31/2016 2.4 months

**NIH/NCI Parent R01** (No cost extension) $1,037,500 total direct

“Mechanisms of the Stromal Response to Smoothened Inhibition in Pancreatic Cancer”

The goal of this proposal is to investigate the molecular mechanisms of observed changes in the stroma of pancreatic tumors following treatment with Hedgehog pathway inhibitors.

**122801 Olive (PI)** 7/1/2012 – 6/30/2016 1.2 months

**American Cancer Society** $800,000 total direct

“Preclinical Evaluation of Parp Inhibition in Pancreatic Cancer”

The goal of this proposal is to evaluate a Parp inhibitor in the context of BRCA2 wild type and deficient pancreatic tumors to determine sensitivity, and to identify biomarkers of resistance versus sensitivity.

**1 U54 CA163111-01 Wang (Co-I)** 09/22/2011 – 07/31/2016 0.6 months

**NIH/NCI Interdisciplinary Research Consortium** Olive: $32,500 total direct

"Myofibroblasts in Gastrointestinal Cancers"

The focus of this project is to study the role of myofibroblasts in gastric and pancreatic cancer. Our role in this cooperative effort is to execute a preclinical intervention trial of the demethylating agent Decitabine in genetically engineered mice with pancreatic cancer.

**1R21CA188857-01 Olive (PI)** 7/1/2014 – 6/31/2016 0.6 months

**NIH/NCI** $261,000 total direct

"Preclinical analysis of a targeted Bmi1 inhibitor in pancreatic cancer"

The goal of this proposal is to investigate the pharmacology and preclinical efficacy of a novel Bmi1 inhibitor, PTC-596 using genetically engineered models of pancreatic ductal adenocarcinoma.

**1R21CA177591-01A1 Stockwell (Co-Inv.)** 4/1/2014 – 3/31/2016 0.5 months

**NIH/NCI** $12,480 total direct

“Discovery of allele-selective KRAS inhibitors”

The goal is to create allele-selective inhibitors of activated KRAS.

**Sponsored Research Project Olive (PI)** 11/1/14 – 10/31/15 0.48 months

**PTC Therapeutics** $100,240 total direct

“Gene expression analysis of the effects of PTC-596 on pancreatic tumors”

RNA-SEQ will be performed on pre- vs. post-treatment pancreatic tumors tumor samples from genetically engineered mice using PTC-596, a targeted Bmi1 inhibitor.

**Sponsored Research Project Olive (PI)** 11/1/14 – 10/31/15 0.48 months

**PTC Therapeutics** $13,750 total direct

“Pilot evaluation of PTC-BDM, a targeted Bmi1 inhibitor”

Supported early pilot studies of a targeted Bmi1 inhibitor.

**Sponsored Research Project Olive (PI)** 11/1/14 – 10/31/15 0.48 months

**Infinity Pharmaceuticals** $80,769 total direct

“Pilot analysis of the preclinical effects of IPI-9119, a fatty acid synthase inhibitor, on a genetically engineered mouse model of pancreatic cancer.”

This study will explore effects of FASN inhibition on pancreatic ductal adenocarcinoma using the KPC mouse model.

**Cancer Research Fellowship Olive (PI)** 7/1/2013 – 6/30/2015 0.6 months

**Stewart Trust** $150,000 total direct

"Preclinical evaluation of Bmi1 inhibitor in Pancreatic Ductal Adenocarcinoma"

Evaluation of PTC-BDM, a Bmi1 inhibitor, in genetically engineered mouse models of pancreatic cancer.

**Bernard L. Schwartz Designated Olive (PI)** 7/1/2010 – 6/31/2013 2.4 months

**Research** **Scholar Award in Pancreatic Cancer** $225,000 total direct

**American Gastroenterological Association**

“The Influence of Hedgehog Pathway Inhibition on Pancreatic Cancer Metastasis”

To investigate the mechanisms by which hedgehog pathway inhibitors influence pancreatic cancer metastasis.

**Translational Innovator Award Olive (PI)** 7/1/2011 – 6/31/2012 0.6 months

**Lustgarten Foundation for Pancreatic Cancer Research** $90,909 total direct

“Preclinical Evaluation of the Mutant-Ras Synthetic Lethal Drug MEII”

The goal of this proposal is to perform a preclinical trial of MEII, a mutant-Ras synthetic lethal compound, using the KPC model of pancreatic cancer.

**197712** **Olive (PI)** 7/1/2011 – 6/31/2013 1.2 months

**AACR/PanCan Career Development Award** $200,000 total direct

“The Role of HIF1α and Hypoxia in Pancreatic Ductal Adenocarcinoma”

The goal of this project is to evaluate the effects of hypoxia on pancreatic tumor development and progression, and the role of HIF1a in this process.

**1 S10 RR025482-01A2S10 Olive (PI)** 6/1/2011 – 5/31/2012 0.0 months

**NIH S10 Equipment Grant** $393,698 total direct

“Micro Ultrasound Scanner to Track Tumor Models”

Equipment grant for the purchase of a Vevo 2100 high resolution ultrasound instrument for the HICCC Small Animal Imaging Shared Resource.

**Cooperative Research Agreement Olive (PI)** 1/1/2011 – 12/31/2011 0.0 months

**Infinity Pharmaceuticals Inc.** $41,667 total direct

“Preclinical Evaluation of Combination IPI-926 + Doxorubicin in Pancreatic Ductal Adenocarcinoma”

The goal of this project is to evaluate the preclinical efficacy of the combination of IPI-926 with Doxorubicin in the KPC model of pancreatic ductal adenocarcinoma.

**2010 Inter-Programmatic Pilot Olive (PI)** 9/1/2010 – 8/31/2011 0.0 months

**Herbert Irving Comprehensive Cancer Center** $60,000 total direct

“Preclinical Studies of PARP Inhibition in Pancreatic Cancer”

The aim of this project is to provide pilot data on the efficacy of a Parp inhibitor in mouse models of BRCA-deficient pancreatic cancer.

**1F32CA123939 Kirschstein NRSA Olive (PI)** 9/25/2006 – 9/24/2009 12 months

**NIH/NCI** $124,380 total direct

“Pre-clinical Evaluation of Novel Therapeutics for PDA”

During this postdoctoral fellowship, I developed the Mouse Hospital platform for preclinical evaluation of novel therapeutics in pancreatic ductal adenocarcinoma.

**Teaching Experience**

*Courses and lectures*

2018 Discussion leader, CMBS Responsible Conduct of Research course, session on “Animal and Human research”

2017 Lecturer, Cold Spring Harbor Course, “Foundations in Pancreatic Cancer Research”

Lecturer, PATH G4500 - “Cellular & Molecular Biology of Cancer”, Columbia University

2016 Lecturer, PATH G4500 - “Cellular & Molecular Biology of Cancer”, Columbia University

Discussion leader, CMBS Responsible Conduct of Research course, session on “Animal and Human research”

2015 Lecturer, PATH G4500 - “Cellular & Molecular Biology of Cancer”, Columbia University

Discussion leader, CMBS Responsible Conduct of Research course, session on “Animal and Human research”

2014 Lecturer, PATH G4500 - “Cellular & Molecular Biology of Cancer”, Columbia University

Discussion leader, CMBS Responsible Conduct of Research course, session on “Animal and Human research”

2013 Lecturer, Cold Spring Harbor Laboratories course, "Foundations of Pancreatic Cancer"

Lecturer, PATH G4500 - “Cellular & Molecular Biology of Cancer”, Columbia University

2012 Lecturer, 5th NKI-Curie Course on Preclinical Assays, Amsterdam, Netherlands

Lecturer, PATH G4500 - “Cellular & Molecular Biology of Cancer”, Columbia University

2011 Teaching Assistant and Lecturer, Cold Spring Harbor Laboratories course, “Foundations of Pancreatic Cancer”

*Graduate Program Affiliations*

2012 – present Pharmacology and Molecular Signaling Program

2010 – present Pathobiology and Molecular Medicine

2010 – present Integrated Program in Cellular, Molecular, and Biomedical Studies

*Qualifying exam committees*

Justin Hickman 2014 Pathobiology and Mol. Med. Advisor: Wei Gu

Ian Tattersall 2011 MD/PhD Advisor: Jan Kitajewski

Sarah Tisdale 2010 Integrated Program Advisor: Livio Pellizzoni

*Thesis committees*

Bill Raab 2017 – present Pathobiology and Mol. Med. Advisor: Piero Dalerba

Jing He 2016 – 2017 Systems Biology Advisor: Andrea Califano

Jesse Handler 2016 NYU- MD/PhD Prgoram Advisor: Dafna Bar-Sagi

Miki Hayano 2015 Pharmacology Program Avisor: Brent Stockwell

Visanthi Viswanathan 2014 Biology Advisor: Brent Stockwell

Irina Jilishitz 2013 – 2015 Integrated Program Advisor: Jan Kitajewski

Gary Hou 2012 – 2013 Biomedical Engineering Advisor: Elisa Konofagou

Ian Tattersall 2012 – 2014 MD/PhD Advisor: Jan Kitajewski

Benjamin Hopkins 2012 – 2013 Pathobiology and Mol. Med. Advisor: Ramon Parsons

Reka Letso 2011 Pathobiology and Mol. Med. Advisor: Brent Stockwell

Rohitha SriRamaratnam 2011 Chemistry Advisor: Brent Stockwell

Colin Palmer 2010 Integrated Program Advisor: Boris Reizis

*Clinical fellow committees*

Sarah Tannenbaum 2013 – 2015 Pediatric Oncology Advisor: Darryl Yamashiro

Charlotte Alme 2011 – 2012 Hematology/Oncology Advisor: Igor Matushansky

**Trainees** (\* indicates current trainees)

*Clinical Fellows*

Gulam Manji 2013 – 2015 Dept. of Medicine, Div. of Hematology and Oncology

Received ASCO Young Investiagator Award. Current: Assistant Professor of Medicine, Columbia University Medical Center. Secured R01 grant from NIH and multiple clinical trials.

Domenico Viterbo 2013 – 2014 Dept. of Medicine, Div. of Digestive & Liver Diseases

Current: Gastroenterologist, Digestive Disease Center of the Hudson Valley

Paul Oberstein 2011 – 2013 Dept. of Medicine, Div. of Hematology and Oncology

Received ASCO Young Investigator Award and KL2 grant.

Current: Chief of GI Medical Oncology, NYU Langone Medical Center

*Adjunct Associate Research Scientist*

Kazuki Sugahara 2013 – 2017 Dept. of Surgery, PGY5

*Postdoctoral Fellows*

Michael Badgley\* 2018 Ph.D., Columbia University

Luis Arnes\* 2016 – present Ph.D., Autónoma University, Madrid, Spain

Hans Carlo Maurer 2015 – 2018 M.D., University of Munich, Germany

Current: Clinical Fellow, University of Munich, Germany

Dafydd Thomas 2010 – 2015 Ph.D., 2010; Temple University, Philadelphia, PA

Current: Scientist, PMV Pharma, Cranberry, NJ

Barbara Orelli 2010 – 2016 Ph.D., 2010; Stony Brook University, Stony Brook, NY

Current: Project Manager, Office of Development and Alumni Affairs, NYU Langone Medical Center

Sam Holmstrom 2012 – 2015 Ph.D., 2005; U. Michigan, Ann Arbor, MI

Current: Senior Research Associate, U.T. Soutwestern Medical Center

Jennifer Jongen 2011 – 2012 University of Utrecht, Utrecht, The Netherlands

Current: Surgeon, University of Utrecht, The Netherlands

*Doctoral Students*

Michael Badgley\* 2011 – 2017 Dept. of Pathology & Cell Biology

Roshan Ahmed\* 2012 – 2018 Dept. of Pharmacology

Jaime Eberle\* 2013 – present Dept. of Pathology & Cell Biology

*Master’s Students*

Brandon Pecchia 2015 – 2016 Nutrition Program

Current: Medical student, New York Medical College

*Undergraduate Students*

Jonathan Parker Spring, 2018 – present Columbia University

Brandon Cuevas Summer, 2017 – present Columbia University

Christina Firl Summer, 2015 – Spring 2017 Columbia University

Peter Kim Fall, 2012 – Spring 2016 Columbia University

Haoxuan Yuan Summer, 2014 – Spring 2017 Columbia University

Peri Shapiro Fall, 2012 – Spring, 2013 Columbia University

Xidi Ma Fall, 2012 – Spring, 2013 Columbia University

*Medical Students*

Tessa LeLonge 2016 ­­– 2017 VU Uni. Medical Center, Amsterdam, The Netherlands

Current: Ph.D. Student, VU Medical Center, Amsterdam, The Netherlands

*Rotation Graduate Students*

Amanda Decker Winter, 2018 Integrated Program, CMBS

Timothy Zhong Fall, 2017 Pathobiology and Molecular Medicine Program

Alyssa Klein Summer, 2015 MD/PhD Program

Jennifer Frevert Fall, 2014 Pharmacology Program

William Raab Fall, 2014 Pathobiology and Molecular Medicine Program

Tiara Ahmed Spring, 2014 Pathobiology and Molecular Medicine Program

Chelsea Dieck Spring, 2014 Integrated Program, CMBS

Claudia Becerra Fall, 2013 Pathobiology and Molecular Medicine Program

Linda Williams Spring, 2013 Pathobiology and Molecular Medicine Program

Shannon Yoo Summer, 2012 Pharmacology Program

Jennifer Crowe Fall, 2011 Pathobiology and Molecular Medicine Program

Angela Xie Fall, 2011 Pathobiology and Molecular Medicine Program

Sarah Tisdale Spring, 2010 Integrated Program, CMBS

*Post-baccalaureate Students*

Karina Hung Fall, 2012 – Spring 2013 CUMC Post-baccalaureate program

*Interns*

Kadeja Moses Summer, 2017 Lafayette College

Laura Polanco Summer, 2016 Lafayette College

Matthew Federbush Summer, 2015 University of Chicago

Tiffany Phuong Summer, 2015 Lafayette College

Farrah Liu Summer, 2015 Autonomous University of Barcelona

Sahityasri Thapi Summer, 2015 Columbia University

Farrah Liu Summer, 2015 The College of New Jeresey

Francine Palermo Summer 2015 Hofstra University

Michael Sigorous Summer, 2014 Tufts University

Wendi Liu Summer, 2014B.A. SUNY Stony Brook

Michael Chen Summer, 2014 B.S. SUNY Stony Brook

Devorah Leventhal Spring, 2014 Brooklyn College

David Wu Fall, 2013 B.S. SUNY Stony Brook

Kaitlyn Bosch Summer, 2013 B.S. Bucknell University

Ian Chabot Summer, 2013 High School student

Matthew Levin Summer, 2012 Northwestern University

Mayté Hernandez-Burgos Summer, 2011 University of Puerto Rico

**Publications**

*Peer reviewed research articles* (\*corresponding or first author). Total of 22, 8 primary author.

1. \*Arnes L, Liu Z, Wang J, Carlo Maurer H, Sagalovskiy I, Sanchez-Martin M, Bommakanti N, Garofalo DC, Balderes DA, Sussel L, Olive KP, Rabadan R. “Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma”, **Gut**, Feb 2018, advance online. PMID: 29440233 Role: Oversaw laboratory component and contributed large-scale RNA-seq dataset; writing and editing.
2. Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC. “β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer”, **Cancer Cell**, 33 (1): 75-90, 2017. PMID: 29249692 Role: Advised on *in vivo* studies and imaging; contributed genetically engineered mice.
3. Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR. “Multivalent Small-Molecule Pan-RAS Inhibitors” **Cell**, 168 (5): 878-889, 2017. PMID: 28235199 Role: Oversaw experiment in KPF/FC mouse model.
4. \*Payen T, Palermo CF, Sastra SA, Chen H, Han Y, Olive KP,\* Konofagou EE.\* “Elasticity mapping of murine abdominal organs *in vivo* using harmonic motion imaging (HMI).” **Phys Med Biol,** 61(15): 5741-54, 2016. PMID: 27401609. Role: Oversaw *in vivo* studies and analysis of tissues; writing and editing.
5. Westphalen CB, Takemoto Y, Tanaka T, Macchini M, Jiang Z, Renz BW, Chen X, Ormanns S, Nagar K, Tailor Y, May R, Cho Y, Asfaha S, Worthley DL, Hayakawa Y, Urbanska AM, Quante M, Reichert M, Broyde J, Subramaniam PS, Remotti H, Su GH, Rustgi AK, Friedman RA, Honig B, Califano A, Houchen CW, Olive KP, Wang TC. “Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis.” **Cell Stem Cell**, 18(4): 441-55, 2016. PMID: 2705893. Role: Advised on *in vivo* studies and imaging, and contributed mice.
6. Chen H, Hou GY, Han Y, Payen T, Palermo CF, Olive KP, Konofagou EE. “Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer.” **IEEE Trans Ultrason Ferroelectr Freq Control**, 62(9): 1662-73, 2015. PMID: 2641512. Role: Oversaw *in vivo* experiments; provided histology; editing.
7. Bednar F, Schofield HK, Collins MA, Yan W, Zhang Y, Shyam N, Eberle JA, Almada LL, Olive KP, Bardeesy N, Fernandez-Zapico ME, Nakada D, Simeone DM, Morrison SJ, Pasca di Magliano M. “Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism”, **Carcinogenesis**, 2015 [epub ahead of print] PMID: 25939753. Role: Contributed an immunohistochemistry experiment.
8. Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA.” Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.” **Clin Cancer Res**. 2015. PMID: 25677697. Role: Advised on imaging techniques and analysis.
9. Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spaliviero M, White JR, Monette S, O'Connor R, Pitter KL, Sastra SA, Saborowski M, Holland EC, Singer S, Olive KP, Lowe SW, Blasberg RG, Kircher MF. “Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging.” **Sci Transl Med.** 7(271):271ra7, 2015. PMID: 25609167. Role: Contributed genetically engineered models.
10. \*Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP\*, Stanger BZ\*. “Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma”, **Cancer Cell**, 25(6): 735 – 747, 2014. Role: Led all pharmacological experiments (Figs. 3-6, S2-S5); intellectual guidance; data analysis; figure preparations; writing; editing.
11. \*Sastra S. and Olive KP. "Acquisition of tumor biopsies through abdominal laparotomy", **Cold Spring Harb Protoc** Cold Spring Harb Protoc. 2014(1):47-56 2014. PMID: 24371318 PMCID: PMC4084730. Role: Developed method; wrote manuscript; prepared figures.
12. DelGiorno KE, Hall JC, Takeuchi KK, Pan FC, Halbrook CJ, Washington MK, Olive KP, Spence J, Sipos B, Wright CVE, Wells JM , Crawford HC.  “Identification and manipulation of biliary metaplasia in pancreatic tumors.” 2013. ***Gastroenterology***, 146(1):233-44, 2014. PMID: 23999170. Role: Contributed mouse tissue samples.
13. \*Sastra SA, Olive KP, "Quantification of murine pancreatic tumors by high-resolution ultrasound." **Methods Mol Biol**. 980: 249-66, 2013. Role: Developed method; wrote manuscript; prepared figures.
14. Shakya R, Gonda TA, Quante M, Salas M, Kim S, Brooks J, Hirsch S, Davies J, Cullo A, Olive KP, Szabolcs M, Wang TC, Tycko B, Ludwig T. "Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma." **Cancer Research**, 73(2): 885-96, 2012. Role: Intellectual contributions; advice on mouse models.
15. Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI. “[A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.](http://www.ncbi.nlm.nih.gov/pubmed/21431415)” **Cancer Chemother Pharmacol,** 68(5):1243-53, 2011. Role: Developed NMR method; generated biological samples; intellectual guidance.
16. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. “Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer.” **Cancer Cell,** 18(5):499-509, 2010. Role: Analyzed histopathology; intellectual contributions.
17. \*Olive KP, Davidson CJ, Jacobetz MA, Honess D, McIntyre D, Madhu B, Goldgraben MA, Frese K, Caldwell ME, DeNicola G, Feig C, Gopinathan A, Combs C, Winter SP, Ireland H, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Iacobuzio-Donahue C, Plunkett W, Egorin M, Hruban RH, McGovern K, Griffiths J, Tuveson DA. “Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer.” **Science**, 324: 1457-1461, 2009. Role: Led entire project; performed all *in vivo* experiments; wrote manuscript; drafted figures.
18. Bertout JA\* & Patel JA\*, Fryer BH, Durham AC, Covello KA, Olive KP, Goldschmidt MH, Simon, MC. “Heterozygosity for Hypoxia Inducible Factor 1 decreases the incidence of thymic lymphosarcomas in a p53 mutant mouse model.” **Cancer Research**, 69(7): 3213- 3220, 2009. Role: Advised on analysis of mouse models.
19. Cook N, Olive KP, Frese K, Tuveson DA. “K-ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.” **Methods in Enzymology**, 439: 73 – 85. Role: Developed concepts; edited manuscript.
20. \*Jackson EL**\*** & Olive KP\*, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. “The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer.”  **Cancer Research**, 65(22): 10280-10288, 2005. Role: Co-led all experiments; co-developed all concepts; co-wrote text and drafted figures.
21. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. “Mice Expressing a Mammary Gland-Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development.*”* **Cancer Research**, v. 65 (18): 8166 – 8173. Role: Contributed to generation of mice.
22. \*Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. “Mutant p53 Gain-of-Function in Two Mouse Models of Li-Fraumeni Syndrome*.”* **Cell**, Vol. 119, 847–860, 2004. Role: Led and performed all experiments; developed concepts; wrote manuscript; drafted figures.

*Review Articles*(\*corresponding or first author) 12 total, 8 primary author.

1. Manji GA, Olive KP, Saenger YM, Oberstein P. “Current and Emerging Therapies in Metastatic Pancreatic Cancer.” **Clin Cancer Res**, 23(7): 1670-1678, 2017. PMID: 28373365. Role: Editing.
2. \*Olive KP. “Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy”, J **Oncol Pract**, 13(3): 181-183 2017. PMID: 28282273
3. \*Olive KP. “Stroma, Stroma Everywhere (Far More Than You Think)” **Clin Cancer Res**, 21(15):3366-8, 2015. PMID: 25979482.
4. \* Holmstrom SR, Olive KP. “Protein breakdown precedes pancreatic tumor development.” **Nature Medicine**, 20(10): 1097-9, 2014. PMID: 25295937. Role: Writing and editing; drafted figures.
5. \*Olive KP, and Politi K, "Translational Therapeutics in Genetically Engineered Mouse Models of Cancer", **Cold Spring Harb Protoc**, Cold Spring Harb Protoc. 2014(2):131-43, 2014. PMID: 24492770. Role: Writing and editing; drafted figures.
6. \*Oberstein PE and Olive KP, "Pancreatic Cancer: Why is it so hard to treat?" **Therapeutic Advances in Gastroenterology**, Advanced Online Publication, March 7, 2013. PMID: 23814611. Role: Writing and editing; drafted figures.
7. Chin L, de Sauvage F, Egeblad M, Olive KP, Tuveson D, Weiss W., “Recapitulating human cancer in a mouse.” **Nat Biotechnol**, 31(5):392-5, 2013. PMID: 23657389. Role: Interview subject.
8. \*Westphalen CB and Olive KP, "Genetically engineered mouse models of pancreatic cancer." **Cancer J**, 18(6): 502-10, 2012. PMID: 23187836. Writing and editing.
9. \*Cox AD and Olive KP. “Silencing the killers: paracrine immune suppression in pancreatic cancer.” **Cancer Cell**, 21(6) 715 – 716, 2012. PMID: 22698396. Writing and editing.
10. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. “Stromal biology and therapy in pancreatic cancer.” **Gut**, 60(6):861-8, 2011. PMID: 20966025. Role: Editing.
11. \*Olive KP and Tuveson DA. *The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics.* **Clin Cancer Res**, 12(18): 5277-5287, 2006. PMID: 17000660. Role: Writing.
12. Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T. *Mouse models of human non-small-cell lung cancer: raising the bar.* **Cold Spring Harb Symp Quant Biol**, 2005;70:241-50. PMID: 16869760. Role: Editing.

*Books*

1. Abate-Shen CA, Politi KP, Chodosh L, and Olive KP. "Mouse Models of Cancer", **Cold Spring Harbor Laboratories Press**, 2014. Role: Editor.

*Other invited publications*

1. Olive, KP. “Ras-dependent paracrine cascades”. National Cancer Institute Ras blog, published August 17, 2017. https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2017/paracrine-cascades

**Invited or Peer-selected presentations**

10/2017 Lecture, “Understanding paracrine interactions in pancreatic ductal adenocarcinoma”, Bristol Myers Squibb symposium on tumor explant models.

8/2017 Lecture, Salk Institute Mechanisms and Models of Cancer Meeting “Leveraging the dependency of pancreatic tumor cells on ROS detoxification”

5/2017 Invited lecture, University of Pennsylvania Basser Institute Symposium on BRCA, “Selective sensitivity of Brca2-mutant pancreatic tumors is dependent on mitotic functions”

11/2016 Invited lecture, Mayo Clinic symposium on pancreatic cancer, “Selective sensitivity of Brca2-mutant pancreatic cancer is dependent on mitotic functions”

5/2016 Invited lecture, Project Purple symposium at University o Nebraska, Omaha, NB. “Compartment-specific regulatory networks in pancreatic cancer”

3/2015 Invited lecture, University of Nebraska, Omaha, NB. “Preclinical Therapeutics in Genetically Engineered Models of Pancreatic Cancer"

11/2014 Invited lecture, University of Michigan, Ann Arbor, MI. “Preclinical Therapeutics in Genetically Engineered Models of Pancreatic Cancer"

4/2014 AACR Annual Meeting, San Diego, CA. "The Role(s) of Tumor Stroma in Pancreatic Cancer

Chemoresistance"

4/2014 AACR Annual Meeting, San Diego, CA. Career Development Session. "How to Distinguish Yourself From

Your Mentor"

3/2014 PTC Therapeutics, South Plainfield, NJ. "Preclinical Therapeutics in Genetically Engineered Models of   
Pancreatic Cancer"

2/2014 Molecular Triconference, San Francisco, CA. "The Role(s) of Tumor Stroma in Pancreatic Cancer

Chemoresistance"

11/2013 Gilead Pharmaceuticals, Foster City, CA. "Preclinical Therapeutics in Genetically Engineered Models of

Pancreatic Cancer"

11/2013 AACR Conference, Translational Preclinical Models in Cancer, San Diego, CA

11/2013 MMHCC Co-clinical trials meeting, BIDM, Harvard Medical, MA “Sharpening the tools: Technological

Innovations for Performing Co-Clinical Trials”

8/2013 Salk Institute Mechanisms and Models of Cancer Symposium, La Jolla, CA. "Paradoxical acceleration of

pancreatic tumorigenesis by Smoothened inhibition: a post-clinical trial"

6/2013 GI Research Academy, Kyoto, Japan. "Paradoxical acceleration of pancreatic tumorigenesis by

Smoothened inhibition: a post-clinical trial"

4/2013 Bruker, AACR Meeting, “Evaluating Mouse Tumor Models Using Compact MRI”

3/2013 Grand Grounds, Winship Cancer Institute, Emory University Cancer Center, Atlanta, GA, “Preclinical

Therapeutics in Genetically Engineered Mouse Models of Pancreatic Cancer”

2/2013 Preclinical Therapeutics, Banbury Course on Pancreatic Cancer, Banbury, NY. "Translational Therapeutics and genetically engineered models of pancreatic cancer".

8/2013 Presentation to NCI Pancreatic Cancer Working Group Teleconference

10/2012 Medical College of Wisconsin, Cancer Cell Biology Seminar Series, Milwaukee, WI, “Preclinical

Therapeutics in Genetically Engineered Mouse Models of Pancreatic Cancer”

9/2012 Netherlands Cancer Institute, “Preclinical Therapeutics in Genetically Engineered Mouse Models of Pancreatic Cancer”

6/2012 Stony Brook University, Dept. of Pharmacology, Student Symposium, Stony Brook, NY, “Therapeutic

Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer”

6/2012 World Pharma Congress, Philadelphia, PA, Therapeutic Intervention Targeting a Hedgehog-dependent

Barrier to Drug Delivery in Pancreatic Cancer”

6/2012 Tufts University, GI Division, Grand Rounds, Boston, MA, Therapeutic Intervention Targeting a

Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer”

6/2012 NIH MMHCC Annual Meeting, Washington DC, “Lessons From the Translation of Smoothened Inhibitors

in Pancreatic Cancer”

6/2012 AACR/PanCAN Pancreatic Cancer Meeting, Lake Tahoe, NV, “Lessons From the Translation of

Smoothened Inhibitors in Pancreatic Cancer”

5/2012 Digestive Diseases Week, San Diego, CA, “ Targeting the Stroma of Pancreatic Cancer”

4/2012 Bucknell University, Biochemistry Seminar Series, Lewisburg, PA, “Therapeutic Intervention Targeting

Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer”

4/2012 AACR Annual Meeting, Chicago, IL, “Meet the expert session: Career Development in Pancreatic Cancer”

2/2012 Yale University, GI Division, Grand Rounds, New Haven, CT, Therapeutic Intervention Targeting a

Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer”

1/2012 ASCO GI Mtg, San Francisco, CA, “Facilitating Drug Delivery in Pancreatic Cancer” and “ Therapeutic

Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer”

11/2011 German Pancreatic Club Annual Meeting, International Invited Speaker, Marburg, Germany,

“Facilitating Drug Delivery in Pancreatic Cancer”

11/2011 University of Pennsylvania, GI Division, Philadelphia, PA, “Therapeutic Intervention Targeting

Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer.”

11/2011 American Pancreatic Association Annual Meeting, Chicago, IL, “Facilitating Drug Delivery in Pancreatic

Cancer”

11/2011 Columbia University Board of Visitors Meeting, Metropolitan Club, NYC, “Facilitating Drug Delivery in

Pancreatic Cancer”

8/2011 University of Colorado, Cancer Imaging Symposium (Keynote Speaker), Boulder, CO, “Using Ultrasound

to Monitor Drug Delivery”

8/2011 Genentech, South San Francisco, CA, “Therapeutic Intervention Targeting a Hedgehog-dependent Barrier

to Drug Delivery in Pancreatic Cancer.”

6/2011 Cold Spring Harbor Course: Foundations in Pancreatic Cancer, NY, two talks (1) “The Non-Immune

Pancreatic Stroma” and (2) “Building the Foundations of a Mouse Hospital”

2011 MMHCC Co-clinical Trials Meeting, Boston, MA. "Bricks and Mortar: Building the Foundations of a Mouse

Hospital"

11/2010 AH&MRC Annual Meeting, International Invited Speaker, Melbourne, Australia, “Therapeutic

Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer”

11/2010 Garvan Institute, Sydney, Australia, “Therapeutic Intervention Targeting a Hedgehog-dependent Barrier

to Drug Delivery in Pancreatic Cancer”

10/2010 Infinity Pharmaceuticals, Cambridge, MA, "Therapeutic Intervention Targeting a Hedgehog-dependent

Barrier to Drug Delivery in Pancreatic Cancer”

7/2010 AACR Translational Medicine (USA), San Francisco, “Identification of a Hedgehog Pathway- Dependent

Barrier to Drug Delivery Using a Kras/p53-Driven Mouse Model of Pancreatic Cancer”

4/2010 AACR Annual Meeting, VisualSonics User’s Meeting, Washington DC, “Imaging Drug Delivery in

Pancreatic Cancer”

3/2010 New York Academy of Science Hedgehog Pathway Meeting, 7 World Trade Center, New York

"Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic

Cancer”